[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL162242A0 - Azaindolylalkylamine derivatives as5-hydroxytryptamine-6 ligands - Google Patents

Azaindolylalkylamine derivatives as5-hydroxytryptamine-6 ligands

Info

Publication number
IL162242A0
IL162242A0 IL16224202A IL16224202A IL162242A0 IL 162242 A0 IL162242 A0 IL 162242A0 IL 16224202 A IL16224202 A IL 16224202A IL 16224202 A IL16224202 A IL 16224202A IL 162242 A0 IL162242 A0 IL 162242A0
Authority
IL
Israel
Prior art keywords
hydroxytryptamine
ligands
azaindolylalkylamine
derivatives
azaindolylalkylamine derivatives
Prior art date
Application number
IL16224202A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of IL162242A0 publication Critical patent/IL162242A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL16224202A 2001-12-20 2002-12-17 Azaindolylalkylamine derivatives as5-hydroxytryptamine-6 ligands IL162242A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34283801P 2001-12-20 2001-12-20
PCT/US2002/040220 WO2003053970A1 (en) 2001-12-20 2002-12-17 Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands

Publications (1)

Publication Number Publication Date
IL162242A0 true IL162242A0 (en) 2005-11-20

Family

ID=23343489

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16224202A IL162242A0 (en) 2001-12-20 2002-12-17 Azaindolylalkylamine derivatives as5-hydroxytryptamine-6 ligands

Country Status (22)

Country Link
US (3) US6800640B2 (xx)
EP (1) EP1456206B1 (xx)
JP (1) JP4339123B2 (xx)
KR (1) KR20040077861A (xx)
CN (1) CN1620455A (xx)
AR (1) AR037907A1 (xx)
AT (1) ATE396191T1 (xx)
AU (1) AU2002360618B2 (xx)
BR (1) BR0215151A (xx)
CA (1) CA2470832C (xx)
CO (1) CO5590960A2 (xx)
DE (1) DE60226775D1 (xx)
DK (1) DK1456206T3 (xx)
ES (1) ES2305338T3 (xx)
IL (1) IL162242A0 (xx)
MX (1) MXPA04005886A (xx)
NO (1) NO20043099L (xx)
PL (1) PL370890A1 (xx)
RU (1) RU2004122094A (xx)
TW (1) TW200301251A (xx)
WO (1) WO2003053970A1 (xx)
ZA (1) ZA200405733B (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2222828B1 (es) 2003-07-30 2006-04-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos.
AU2004297235A1 (en) 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
MXPA06014471A (es) 2004-06-09 2007-03-21 Glaxo Group Ltd Derivados de pirrolopiridina.
CA2579087C (en) 2004-09-03 2012-05-01 Yuhan Corporation Pyrrolo[2,3-c]pyridine derivatives and processes for the preparation thereof
KR100946220B1 (ko) * 2004-09-03 2010-03-08 주식회사유한양행 피롤로[3,2-ｃ]피리딘 유도체 및 그의 제조방법
KR101142363B1 (ko) 2005-06-27 2012-05-21 주식회사유한양행 피롤로피리딘 유도체를 포함하는 항암제 조성물
EP1947085A1 (en) * 2007-01-19 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituted indole sulfonamide compounds, their preparation and use as medicaments
BRPI0812360A2 (pt) * 2007-05-21 2015-01-27 Sgx Pharmaceuticals Inc Compostos moduladores de quinase heterocíclica e método de modulação da atividade de uma proteína tirosina quinase
AU2008256859A1 (en) * 2007-05-24 2008-12-04 Memory Pharmaceuticals Corporation 4' substituted compounds having 5-HT6 receptor affinity
US20100016297A1 (en) * 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100022581A1 (en) * 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
US20100029629A1 (en) * 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
US20100056531A1 (en) * 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US8592448B2 (en) * 2008-11-20 2013-11-26 OSI Pharmaceuticals, LLC Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
US8119683B2 (en) * 2009-08-10 2012-02-21 Taipei Medical University Aryl substituted sulfonamide compounds and their use as anticancer agents
US20130072495A1 (en) 2010-05-14 2013-03-21 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
JP2014515368A (ja) 2011-05-26 2014-06-30 第一三共株式会社 プロテインキナーゼ阻害剤としての複素環化合物
RU2631482C2 (ru) 2011-07-22 2017-09-22 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Композиция
CN104755480B (zh) 2012-08-24 2017-04-12 葛兰素史克有限责任公司 吡唑并嘧啶化合物
RU2643371C2 (ru) 2012-11-20 2018-02-01 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Новые соединения
WO2014081643A1 (en) 2012-11-20 2014-05-30 Glaxosmithkline Llc Novel compounds
RS56233B1 (sr) 2012-11-20 2017-11-30 Glaxosmithkline Llc Nova jedinjenja
CN102977094A (zh) * 2012-11-30 2013-03-20 盛世泰科生物医药技术(苏州)有限公司 一种2-羟基-1,5-萘啶的合成方法
WO2015090233A1 (en) 2013-12-20 2015-06-25 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
WO2016004882A1 (en) 2014-07-08 2016-01-14 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
CA3058216C (en) 2017-03-30 2023-08-15 Xw Laboratories Inc. Bicyclic heteroaryl derivatives and preparation and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977131A (en) 1997-04-09 1999-11-02 Pfizer Inc. Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
EP1173432B9 (en) * 1999-04-21 2008-10-15 NPS Allelix Corp. Piperidine-indole compounds having 5-ht6 affinity
CA2382247C (en) * 1999-08-12 2010-09-28 Nps Allelix Corp. Azaindoles having serotonin receptor affinity
US6476034B2 (en) 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
KR100985140B1 (ko) * 2001-12-20 2010-10-05 와이어쓰 엘엘씨 5-하이드록시트립타민-6 리간드로서의 인돌릴알킬아민 유도체
MX2007007206A (es) * 2004-12-14 2008-03-26 Wyeth Corp Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos.

Also Published As

Publication number Publication date
AR037907A1 (es) 2004-12-22
KR20040077861A (ko) 2004-09-07
AU2002360618B2 (en) 2009-01-08
ATE396191T1 (de) 2008-06-15
DE60226775D1 (de) 2008-07-03
BR0215151A (pt) 2004-10-19
US20030171395A1 (en) 2003-09-11
JP4339123B2 (ja) 2009-10-07
JP2005519046A (ja) 2005-06-30
CA2470832A1 (en) 2003-07-03
EP1456206A1 (en) 2004-09-15
US7585876B2 (en) 2009-09-08
MXPA04005886A (es) 2004-09-13
US20080114023A1 (en) 2008-05-15
WO2003053970A1 (en) 2003-07-03
CA2470832C (en) 2010-09-21
US6800640B2 (en) 2004-10-05
EP1456206B1 (en) 2008-05-21
NO20043099L (no) 2004-08-17
CO5590960A2 (es) 2005-12-30
US7297705B2 (en) 2007-11-20
DK1456206T3 (da) 2008-09-08
ZA200405733B (en) 2005-10-19
PL370890A1 (en) 2005-05-30
CN1620455A (zh) 2005-05-25
US20050020598A1 (en) 2005-01-27
AU2002360618A1 (en) 2003-07-09
ES2305338T3 (es) 2008-11-01
RU2004122094A (ru) 2005-03-27
TW200301251A (en) 2003-07-01

Similar Documents

Publication Publication Date Title
IL162242A0 (en) Azaindolylalkylamine derivatives as5-hydroxytryptamine-6 ligands
IL160701A0 (en) 3-substituted-4-pyrimidone derivatives
ZA200309522B (en) Substituted cyclohexane-1-4diamine derivatives
AU2002240751A8 (en) Targeted ligands
IL155443A0 (en) 1- aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
HK1066218A1 (en) Qunazoline derivatives as antitumor agents
AU2002349297A8 (en) Statin-like compounds
IL157059A0 (en) 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
IL158445A0 (en) Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
IL158388A0 (en) Novel arylheteroalkylamine derivatives
GB0102668D0 (en) Compounds
AU2003272511A8 (en) Cd44-binding ligands
HK1065949A1 (en) Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
HUP0303449A3 (en) Substituted benzofuran-2-carboxamides derivatives
IL158448A0 (en) Heterocyclylalkoxy- alkylthio-and-alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
HUP0303186A3 (en) 4-aminobenzopyran derivatives
HUP0401949A3 (en) 4-imidazolin-2-one derivatives
HUP0500026A3 (en) N-heteroarylnicotinamide derivatives
GB0102665D0 (en) Compounds
GB0012054D0 (en) Ligands
HK1068607A1 (en) Phenylalkyloxy-phenyl derivatives
GB0226374D0 (en) Ligands
MXPA03008394A (es) Derivados de biuretano.
EP1364954A4 (en) Dicarba closo DODECARBORANDERIVATE
GB0115841D0 (en) Ligand